Why Moderna's COVID Vaccine Has a 'Huge Advantage' Over Pfizer's
Moderna's COVID vaccine is easier to store, transport, and prepare than Pfizer's, experts have told Newsweek, giving it a "huge advantage" if and when the time comes for them to be rolled out across the U.S.
On November 9, American pharmaceutical firm Pfizer and German biotechnology company BioNTech announced their COVID vaccine was 90 percent effective at preventing the disease. A week later on Monday, biotechnology firm Moderna claimed its vaccine was 94.5 percent effective.
Both announcements were made in press releases, and the results have not yet been published in peer-reviewed journals, prompting experts to state that any excitement should be tempered with caution. Moderna and Pfizer are now waiting to meet certain criteria before applying to the U.S. Food and Drug Administration (FDA) for authorization to vaccinate the general population.
Pfizer vs. Moderna
As the news provided hope that the vaccines may end the COVID pandemic, questions arose over how they would be distributed, particularly as Pfizer's needs to be stored at an "ultra-cold" -70 C, and Moderna's at -20 C. This is because, unlike the flu vaccine that can be kept for up to a year in a fridge, they contain genetic material called mRNA that degrades at room temperature.
https://www.msn.com/en-us/health/medical/why-modernas-covid-vaccine-has-a-huge-advantage-over-pfizers/ar-BB1b68jP?ocid=DELLDHP&li=BBnb7Kz
= new reply since forum marked as read
